| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6906055 | ABBVIE | Phosphonocephem compound |
Dec, 2021
(2 years ago) | |
| US6417175 | ABBVIE | Phosphonocephem derivatives, process for the preparation of the same, and use thereof |
Apr, 2022
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7419973 | ABBVIE | Phosphonocephem compound |
Dec, 2021
(2 years ago) | |
| US9629861 | ABBVIE | Compositions and methods for treating bacterial infections using ceftaroline |
Sep, 2030
(6 years from now) | |
| US8247400 | ABBVIE | Cephem compounds useful for the treatment of bacterial infections |
Feb, 2031
(6 years from now) | |
Teflaro is owned by Abbvie.
Teflaro contains Ceftaroline Fosamil.
Teflaro has a total of 5 drug patents out of which 3 drug patents have expired.
Expired drug patents of Teflaro are:
- US7419973
- US6906055
- US6417175
Teflaro was authorised for market use on 29 October, 2010.
Teflaro is available in powder;intravenous dosage forms.
Teflaro can be used as methods for treating bacterial infections, method of treating bacterial infections.
Drug patent challenges can be filed against Teflaro from 29 October, 2014.
The generics of Teflaro are possible to be released after 10 February, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 13, 2022 |
| New Chemical Entity Exclusivity(NCE) | Oct 29, 2015 |
Drugs and Companies using CEFTAROLINE FOSAMIL ingredient
NCE-1 date: 29 October, 2014
Market Authorisation Date: 29 October, 2010
Treatment: Method of treating bacterial infections; Methods for treating bacterial infections
Dosage: POWDER;INTRAVENOUS
TEFLARO family patents
